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urinary incontinence domain of Expanded Prostate Cancer Index Composite-26 (EPIC-26) in co-
horts from the USA, Norway and Spain.
Methods: A prospective study of pre- and 1-year post-treatment responses in American
(nZ537), Norwegian (nZ520) and Spanish (nZ111) patients, establishing the prevalence of
urinary incontinence defined according to published dichotomization. Thereafter we focused
on the response alternatives “occasional dribbling”, pad use and problem experience. A multi-
variate logistic regression analysis (significance level  0.01) considered risk factors for “not
retaining total control”.
Results: Compared to the European men, the American patients were younger, healthier and
more presented with lower risk tumors. Before RP no inter-country differences emerged the(A.H. Storås).
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162 A.H. Storås et al.prevalence of urinary incontinence (6%). One-year post-treatment urinary incontinence was
described by 30% of the American and 41% of the European patients, occasional dribbling being
the most frequent type of urinary leakage. In the multivariate analysis the risk of “not retain-
ing total control” increased almost 3-fold in European compared to American patients, with
age and co-morbidity being additional independent risk factor.
Conclusion: After RP patients from Spain and Norway reported more unfavorable outcomes by
EPIC-26 than the American patients to most of the urinary incontinence items, the difference
between the European and American patients remaining in the multivariate analysis. The most
frequent post-RP response alternative “occasional dribbling” needs to be validated with pad
weighing as “gold standard”.
ª 2020 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
After radical prostatectomy (RP) prostate cancer (PCa)
patients have a long expected lifetime, the 15-year
cause-specific survival being 88%e93% [1,2]. Conse-
quently, treatment-related adverse effects may have a
long-lasting impact on the survivors’ quality of life, with
urinary incontinence being one of the most common
adverse effects [3e5].
In today’s practice, many PCa patients search for in-
formation about where to expect the best oncologic
outcome, together with the least risk of adverse effects.
The surgeons and the health administrators are also eager
to know whether the treatment given in their institution at
least fulfills published standard expectations. However in
published studies, the rates of post-RP urinary incontinence
vary considerably between institutions and countries [6e8].
Some of these differences are associated with differences
in patient selection, in surgical approaches and/or not at
least on varying definitions of urinary incontinence.
Further, most reviews summarizing single institution or in-
ternational experience are based on cross-sectional obser-
vations of adverse mainly physician-assessed effects.
During the last 2 decades it has become evident that the
evaluation of any post-RP results requires the assessment of
patient-reported outcomes (PROs) of dysfunctions and
bother, preferably observed in longitudinal studies. Vali-
dated and reliable questionnaires have been developed for
this purpose [9]. Using one of the available instruments
several national uro-oncological research groups have
published their experience achieved during 10e15 years. To
facilitate improved inter-study comparison of PROs after
treatment for PCa an international consensus group has
recommended the use of the Expanded Prostate Cancer
Index Composite-26 (EPIC-26) [10]. However, to the best of
our knowledge, only the American-Japanese collaboration
has resulted in inter-country comparisons of post-RP uri-
nary adverse effects, based on EPIC instruments [11e13].
Our group has previously compared the incidence of post-
RP erectile dysfunction as emerging from responses to EPIC-
26 completed by American, Spanish and Norwegian patients
[14], but comparison of urinary incontinence was not pre-
viously done for European-American cohorts.The current exploratory study meets this challenge
regarding patient-reported post-RP urinary incontinence
by comparing the responses of the items in the urinary
incontinence domain of EPIC-26 reported by patients
from America, Spain and Norway, before, and 1 year after
prostatectomy. We hypothesized that the unadjusted rate
of self-reported urinary incontinence would differ be-
tween the patient groups’ 1-year postoperative, but that
differences would disappear after adjusting for possibly
predictive variables as age, co-morbidity and treatment
factors.2. Material and methods
2.1. Study design and patients
This study represents continuing collaboration between
research groups from USA (Prostate Cancer Outcomes and
Satisfaction Treatment Quality Assessment [PROSTAQA]),
Norway (Norwegian Urological Cancer Group [NUCG]) and
Spain (Multicentric Spanish Group of Clinically Localized
Prostate Cancer, Barcelona) [14,15]. The American patients
were treated between 2003 and 2006 at nine university-
affiliated hospitals. The Norwegian patients were included
from 2008e2010, 14 of 19 hospitals performing RP in Nor-
way at that time participated in the study. The Spanish
patients were treated from 2003e2005 at two different
hospitals. After approval by local ethical committees, a de-
identified research data file was created, comprising indi-
vidual pre- and post-treatment data for the American,
Norwegian and Spanish patients, who fulfilled the following
eligibility criteria:
- Histologically confirmed PCa
- Clinical stage T1 or T2 tumor
- Known level of pre-treatment prostate-specific antigen
(PSA) and Gleason score
- Retropubic, laparoscopic or robot-assisted RP with or
without nerve-sparing surgery (unilateral vs. bilateral),
though without further details regarding the extent of
the surgical procedure.
- No neo-adjuvant androgen deprivation therapy
Differences of post-prostatectomy urinary leakage 163- Valid responses to all items in the urinary incontinence
domain of EPIC-26 before (Baseline) and 1 year after
RP [15,16], implying no missing responses to the
questionnaire.
The file also contained medical and socio-demographic
data (co-morbidities, PCa risk group, age, education and
partnership) and information on the surgical approach
(nerve-sparing RP: Bilateral, unilateral or no).
2.2. Clinical variables
The risk groups were defined according to European Guide-
lines on Prostate Cancer treatment from 2012 [17]. Low-risk:
cT1-T2a and Gleason score 6 and PSA <10 ng/mL. Inter-
mediate risk: cT2b-T2c and Gleason score 7 and PSA
10e20 ng/mL. High risk: cT3a and/or Gleason score 8e10
and/or PSA >20 ng/mL.
2.3. Pre-treatment variables
Level of education was dichotomized into “less than high
school” (low) and “high school or more” (high). Relation-
ship status was dichotomized into “no paired relationship”
versus “paired relationship”. Co-morbidity was patient-
reported as the presence of at least one of the following
adverse health conditions: 1. Diabetes; 2. Heart failure
and/or myocardial infarction and/or angina; 3. Stroke; 4.
Peptic ulcer and/or irritable bowel disease; 5. Asthma,
bronchitis and/or breathing problems.
2.4. EPIC-26
The present study is based on the patients’ responses to the
urinary domain of EPIC-26 or EPIC-50 before treatment and
1 year after RP [15,16,18,19]. All items in EPIC-26 are found
with identical wording in the EPIC-50. The urinary inconti-
nence domain of EPIC-26 contains four items assessing
functional aspects (urinary leakage, urinary control and pad
use) and the patient’s problem experience. All four items
have four or five response alternatives. For separation of
self-reported urinary continence from incontinence we
applied Sanda et al’s proposal [20] for dichotomization of
the response alternatives [20]: Urinary incontinence during
the preceding 4 weeks is reflected by one of the following
responses:
- Leakage more than once daily
- Frequent dribbling/no urinary control whatsoever
- Use of  one pad daily and/or
- Having any problem with dribbling or leakage of urine
Importantly, occasional dribbling without use of pads is
not considered to indicate urinary incontinence.
The proportions of patients with urinary incontinence
before and after RP were established for each country, and
the post-RP changes were described. Thereafter and
restricted to patients reporting “total control” pre-
treatment, the numbers of patients with post-RP “pad
use” and “problem” were analyzed.2.5. Statistics
PASW for PC version 21 (IBM Chicago, IL, USA) was used.
Proportions and percentages described binary variables
with chi-square tests assessing between different coun-
tries. To explore possible associations between pre- and
peroperative variables and not retaining “total control”
(“occasional dribbling”, “frequent dribbling” and “no
urinary control whatsoever”) 1 year post treatment, bi-
nary and multivariate logistic regression analyses were
performed, the independent variables being country of
RALP, age, co-morbidity, risk group, and performance of
nerve-sparing surgery. Variables with a p-value <0.05 in
the binary analyses were included in the multivariate
model. Results from logistic regression analyses were
expressed as odds ratios (ORs) and 95% confidence in-
tervals (CIs). The p-values <0.01 were considered sta-
tistically significant. All tests were two-sided.3. Results
3.1. Patients
Records for 1353 eligible patients were available. Due to
one or more missing answer(s) in the urinary incontinence
domain at baseline and/or at 1 year post-RP, 185 patients
(USA, nZ66; Norway, nZ107 and Spain, nZ12) were
excluded from the analyses leaving 1168 evaluable patients
(USA, nZ537; Norway, nZ520; Spain, nZ111).
Compared to the Norwegian and Spanish patients, the
American patients were younger, and fewer had co-
morbid conditions (Table 1). A higher proportion of the
American patients had education above high school level
and more had low risk tumors. Bilateral nerve-sparing RP
was performed more often in the US material, and more
of these had no erectile dysfunction before RP. Except
for age, the values for all described variables were more
favorable for the Norwegian than for the Spanish
patients.
3.2. Urinary incontinence domain
Before RP 66 men fulfilled at least one criterion for uri-
nary incontinence with no significant inter-country dif-
ferences (Table 2). However, 16% of the American, 31% of
the Norwegian and 11% of the Spanish patients re-
ported “occasional dribbling” preoperatively (data not
shown)dmost of them without use of pads. Overall only
2% of the men used pads and only 5% met the criteria for
urinary incontinence. One year after treatment (Table 2)
significant differences between American and both Eu-
ropean groups emerged for all four criteria indicating
urinary incontinence, with more favorable outcomes
among the American than among the European men, in
particular regarding pad use. At that time 40% of all
American and Spanish patients and 66% of the Norwegian
men reported “occasional dribbling”dmost of them
without pad use. Post-RP urinary incontinence was re-
ported by respectively 30% of the American, 41% of the
Table 1 Patient characteristics.
Variable, n (%) USA Norway Spain p-Value Total








<65 year 406 (76) 318 (61) 57 (51) <0.01 <0.01 n.s. 781 (67)
Median age, year 59.9 63.5 64.7 62.3
No co-morbid
condition, n (%)
459 (86) 369 (71) 73 (66) <0.01 <0.01 <0.01 901 (77)




459 (86) 268 (52) 8 (7) <0.01 <0.01 <0.01 735 (63)
PSA mean, SD 6.6 (0.5e54) 9.9 (1.6e75) 7.9 (3.8e23) <0.01 <0.01 <0.01 8.0 (0.5e75)
Gleason score, n (%) a
6 331 (62) 245 (47) 63 (57) <0.01 <0.01 n.s 639 (55)
7 181 (34) 228 (44) 44 (40) 453 (40)
8 25 (5) 47 (9) 3 (3) 75 (6)
T category, n (%)
T1 388 (72) 323 (62) 72 (65) <0.01 n.s. n.s. 783 (67)
T2a 116 (22) 119 (23) 32 (29) 267 (23)
T2b 20 (4) 44 (8) 7 (6) 71 (6)
T2c 13 (2) 34 (7) 0 (0) 47 (4)
Risk group, n (%) b
Low 289 (54) 162 (31) 45 (41) 0.01 0.01 0.01 496 (43)
Intermediate 215 (40) 293 (56) 62 (56) 570 (49)
High 33 (6) 65 (13) 4 (4) 102 (9)
Nerve-sparing, n (%) c
Bilateral 429 (80) 235 (45) 23 (21) <0.01 <0.01 <0.01 687 (59)
Unilateral 62 (12) 141 (27) 5 (5) 208 (18)






434/522 (83) 363/496 (73) 64/111 (58) <0.01 <0.01 <0.01 861 (76)
n.s., no significant; SD, standard deviation.
a Value missing for one patients.
b Erection firm enough for intercourse.
c Value missing for three patients.
164 A.H. Storås et al.Norwegian and 42% of the Spanish patients, the differ-
ence being significant between the American and
European patients (p<0.01). Except for “frequent drib-
bling”/“no urinary control” (p<0.01) the differ-
ences between Norwegian and Spanish patients were
insignificant.
Overall, 35% of the American patients experienced any
change from their pre-treatment level of urinary control
compared to 50% of the Norwegian and 62% of the Spanish
patients (Fig. 1). In most patients the change covered
one step of decreased urinary control, most often the
change from “total control” to “occasional dribbling”.3.3. Urinary control, pad use and problem post-
prostatectomy for patients reporting “total control
is included” pre-treatment
Fig. 2 provides detailed information of the post-RP changes
observed among 891 men with preoperative “total con-
trol”. Respectively 60%, 32% and 35% of the American,
Norwegian and Spanish patients maintained total urinary
control 1 year after RP. After RP, 96 of 441 American men
(22%) compared to 157 of 450 European patients (35%) used
at least one pad daily (p<0.001). The most frequent change
was from “total control” to “occasional dribbling” reported
Table 2 Dichotomized responses of the items in the urinary incontinence domain, pre-treatment and post-treatment.


















11 (2) 5 (1) 4 (4) n.s 21 (4) 41 (8) 28 (25) <0.01b,c,d




7 (1) 12 (2) 4 (4) n.s 42 (8) 100 (20) 30 (27) <0.01b,c
Incontinencea 36 (7) 22 (4) 8 (7) n.s 160 (30) 216 (41) 48 (42) <0.01b,c
EPIC, Expanded Prostate Cancer Index Composite; n.s., no significant.
a Leakage >1x per day and/or frequent dribbling/no urinary control and/or pad use 1 per day and/or moderate or big leaking
problem, 1x per day means “more than one time per day”.
b USA vs. Norway.
c USA vs. Spain.
d Norway vs. Spain.
Differences of post-prostatectomy urinary leakage 165by 37%, 61% and 41% of the men prostatectomized in the
three countries. Within this leakage category the preva-
lence of pad use was similar in the American and Norwegian
patients (about 50%), but was only 31% in the Spanish
cohort of only 12 patients. Inter-country differences
emerged regarding problem experience, reported by
respectively 8%, 17% and 21% of the American, Norwegian
and Spanish patients (p<0.001 for the inter-continental
difference).
3.4. Logistic regression analyses
Table 3 shows ORs and 95% CIs from the bi- and multivariate
analyses performed in patients with pre-treatment “total
control”. In the bivariate analyses significantly higher ORs
for not maintaining “total control” emerged for age 65
years, reporting comorbidity, the diagnosis of a high-risk
tumor, omission of bilateral nerve-sparing RP and being
operated in Europe (Norway or Spain). In the multivariate
analysis being operated in Europe (Norway or Spain) andFigure 1 Change in urinary control from pre-treatment to
1 year postoperative. (Steps of item 2 of EPIC-26: Total control-
occasional dribbling-frequent dribbling-no urinary control).
EPIC, expanded prostate cancer index composite-26.having at least one co-morbid condition remained the only
significant factors for not maintaining “total control”. The
risk of losing “total control” was about tripled for the Eu-
ropean patients compared to the American patients
(ORZ2.7). In multivariate analysis with “pad use” and
“urinary problem” being the dependent variables and
adjusting for the same variables as mention above, the
results were principally the same (data not shown).
4. Theory/calculation
Interpretation of inter-study results regarding post-RP uri-
nary incontinence must be based on consideration of pre-
treatment variables and a valid assessment methodology.
This study attempts to fulfill these requirements.
5. Discussion
5.1. Main findings
This study, based on pre- and post-RP data, is the first to
compare self-reported 1-year postoperative urinary
leakage between patients from USA and Europe. Impor-
tantly, the results are based on the internationally recom-
mended and validated EPIC-26 questionnaire [10,17] and on
definitions of urinary incontinence, which includes the use
of only one pad per day (“safety pad”) [21]. Before RP 5% of
the patients were identified with urinary incontinence,
without significant inter-country differences. After RP
significantly fewer American than European patients met
the criteria for urinary incontinence (30% vs. about 40%),
with occasional dribbling being the most frequent leakage
category. Restricted to patients with preoperative total
control and in a multivariate analysis adjusted for age, co-
morbidity and nerve-sparing operation technique, the risk
of not retaining this leakage category after the RP was
significantly increased among European compared to
American patients.
Figure 2 Functional level, pad use and urinary problem 1 year after RP among 891 patients with total control pre-treatment. RP,
radical prostatectomy; Freq, frequent.
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In this study we used the items of the urinary incontinence
domain of the EPIC-26 questionnaire. This instrument was
recently recommended for comparative evaluations of post-
RP adverse effects [10] in an attempt to harmonize PCa
patients’ report of dysfunction and bother from different
studies. The urinary incontinence domain has shown satis-
factory reliability and discriminative validity [16,19], but
has never been validated against pad weighing as the “gold
standard”. The international consensus group did not pro-
vide any guidelines for interpretation or definition of urinary
incontinence based on EPIC-26. In this situation many clin-
ical investigators, as also our group, use the dichotomization
proposed by Sanda et al. [20] based on experience from
1 201 patients [14]. By use of this dichotomization, and
in agreement with Namiki et al. [11] the greatest
postoperative change of urinary control emerged regardingpad use for our patients from the three countries. However,
much of our study’s post-RP inter-country variability re-
mains unexplained, not at least regarding the need and
prevalence of pad use within the “occasional dibbling”
category. For example, before RP the overwhelming ma-
jority of Norwegian patients with occasional dribbling (31%)
did not use pads, the comparable figure being 16% for men
from USA. After RP about half of the American and Norwe-
gian patients within this leakage category used pads, being
classified as incontinent. Significant inter-continental dif-
ferences were also revealed regarding problem experience
in men reporting this degree of urinary leakage. These ob-
servations as to pad use and problem experience indicate
that the “occasional dribbling category” in EPIC-26 is rather
heterogeneous as to the true amount of leaking urine.
Following Sanda et al. [20] the proportion of pad-free
patients 1 year after RP is in our study viewed as measure
of post-RP urinary incontinence [21]. Admittedly, the
Table 3 OR, 95% CI of not retaining “total control” 1 year post-treatment, bivariate and multivariate analysis. Only patients
with “total control” pre-treatment were included.
Bivariate Multivariate
OR (95% CI) p-Value OR (95% CI) p-Value
Age
65 year 1.6 (1.2e2.1) <0.01 1.3 (1.0e1.8) 0.09
<65 year 1 1
Co-morbidity,
1 co-morbidity 1.9 (1.4e2.7) <0.01 1.6 (1.1e2.2) 0.01
No 1 1
Risk group
Intermediate 1.2 (0.9e1.6) 0.18 1.3 (0.7e1.3) 0.3
High 1.8 (1.1e2.9) 0.03 0.9 (0.6e1.2) 0.3
Low 1 1
Nerve sparing
No 1.9 (1.4e2.6) <0.01 1.1 (0.8e1.6) 0.6
Unilateral 1.5 (1.1e2.1) 0.02 1.1 (0.7e1.7) 0.6
Bilateral 1 1
Site
Europe (Spain and Norway) 2.7 (2.0e3.6) 2.7 (2.0e3.7) <0.01
USA 1 <0.01 1
CI, confidence intervals; OR, odds ratios.
Differences of post-prostatectomy urinary leakage 167shown variations as to “occasional dribbling” and the use of
safety pad are possibly in part explained by non-identified
differences for example cultural disparities, as discussed
by Namiki et al. [13], Johnson et al. [22] and Lee et al. [23].
On the other hand the availability of suitable protection
aids can also play a role.
The criterion of pad-freedom seems thus to be too
insensitive to indicate the true amount of urinary leakage.
The performance of quantitative validation studies of EPIC-
26 (pad-weighing among men with occasional dribbling) is
required for increased understanding of the need and use of
“safety pads”, the latter by many, but not all, clinicians
viewed as expression of urinary continence [24,25].
5.3. Risk factors
In agreement with previous studies age, co-morbidity, risk-
group and nerve-aparing RP were in bivariate analyses
associated with not retaining “total control” after RP,
[6,8,26e29]. However, in part contrary to our hypothesis,
and combining the two European countries, the site of RP
persisted in the multivariate analysis as the highest risk
factor for loss of total control whereas the role of nerve-
sparing RP no longer was significant. Except for small
numbers we can only speculate about possible reasons for
this inter-continental risk difference such as the experience
of the responsible urologist with the different techniques of
nerve-sparing RP [30,31]. Less use of nerve-sparing tech-
niques in the European counties (Table 1), probably related
to delayed introduction explains in part our inter-
continental risk difference. In addition, pre-RP variations
of occasional dribbling (Table 1) and the previously
demonstrated higher prevalence of sexual dysfunction
among the European men within the collected samples [15]
may have contributed to the higher risk of urinary leakageamong the European patients as compared to the American
patients [32].
5.4. Limitations and strengths
Our study has several limitations. First, except for age and
co-morbidity, we do not have sufficient data to completely
explain the shown inter-country risk differences. For
example, no data were available regarding the intensity of
pelvic floor training or postoperative complications. We do
neither have data on type of intervention used in the in-
dividual patient (robotic or laparoscopic or open surgery) or
the number of surgeons performing RP at each center.
However, as far as we know, only minor, if any, differences
of adverse outcomes are documented between the treat-
ment modalities [6,8,32,33].
Second, in the current study we used pre-treatment and
1 year follow-up data. This postoperative time point may be
considered “too early”. However, most, studies have shown
little change in urinary function beyond 12 months
[17,34e37]. Third, our non-randomized patients represent
men operated between 2003 and 2010 with intra-prostatic
tumors, with most American patients operated 3e4 years
before the European ones. The results may be different
today, with the increased experience with nerve-sparing
procedures in the European countries. On the other hand,
today’s increasing number of patients operated with high-
risk prostate cancer may counteract the attempt to
decrease urinary incontinence rates. Fourth, as discussed
above, a more objective measure like pad-weight test
would have provided objective measures. Finally, the low
number of patients in the Spanish group did not always
permit reasonable statements and comparisons for this
country, therefore sometimes providing European vs.
American findings.
168 A.H. Storås et al.The comparison of prospectively collected longitudinal
pre- and post-RP data on patient-reported outcomes from
three recognized international on co-urological research
groups enabling analysis of changes is viewed as a strength,
as few such comparative studies have been published so
far. The use of the internationally recommended EPIC-26
questionnaire and its inherent we show challenges inherent
to this instrument and its interpretation of the urinary in-
continence when applied in an inter-country study war-
ranting future validation studies.
6. Conclusion
One year after RP, patients from Europe (Spain and Norway)
reported more unfavorable outcomes by EPIC-26 than the
American patients to most of the urinary incontinence
items, the difference remaining in the multivariate anal-
ysis. The response alternatives “occasional dribbling” and
“1x pad use” of EPIC-26 should be validated with pad
weighing as “gold standard”.
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Critical revision of the manuscript: Anne Holck Storås,
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